Asthma. Asthma , Status asthmaticus
Conditions
Interventions
Intervention 1: Intervention group: Salmeflo 125/25 , 2 puffs BID. Intervention 2: Control group: Seretide 125/25, 2 puffs BID.
Treatment - Drugs
Intervention group: Salmeflo 125/25 , 2 puffs BID
Control group: Seretide 125/25, 2 puffs BID
Sponsors
Sadaf Darou Saba Company
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients aged 18 years and older who are willing to participate and sign a consent form; Patients who have the ability of using the inhaler with correct technique; exclusion criteria: Using of Inhaled Corticosteroid or Long Acting Beta Agonist in the last month before entering the study; patients with known hypersensitivity to Beta 2 agonist or Inhaled Corticosteroid; patients with lower respiratory system's infection (abnormal chest X ray) during the study; Alcoholics, drugs abuser; Patients who are pregnant or breastfeeding; Patients who use drug for another asthma trial; Patients with another severe and uncontrolled chronic disease, such as Heart failure, FC III, IV and history of myocardial infarction; Patients who show symptoms of acute reactions during the study; Non-compliance patient with treatment protocols; Requiring to use oxygen or systemic corticosteroid during the study; Disability to record the use of rescue medication accurately.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of averages of FEV1. Timepoint: Before study, Every 4 weeks after study. Method of measurement: by Spirometry.;Comparision of disease management. Timepoint: Before Study, Every 4 weeks after study. Method of measurement: ACT query. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Ronak Saadati
Sadaf Darou Saba Company
Outcome results
None listed